The Justice Department and the U.S. Attorney’s Office in Massachusetts have opened investigations into the pricing of four Johnson & Johnson drugs.

The probes are focused on the psoriasis treatment Stelara, arthritis drugs Simponi and Remicade; and hepatitis C drug Olysio, according to the company’s quarterly filing with the Securities and Exchange Commission.

In April, the U.S. Attorney’s Office subpoenaed J&J for documents on its copayment support programs for Olysio, Stelara and Simponi to review how the company reports the prices of those products to the Centers for Medicare & Medicaid Services. The state is also investigating how the firm discloses rebate payments to Massachusetts’ Medicaid agencies.